AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04413019 — intervention group
Intervention type: OTHER
Intervention: Clinical follow up
Description: Patients recruited in this study commenced antibiotic treatment according to the recent guidelines :~* Erythromycin 250 mg 4 times daily for 10 days following the diagnosis of PPROM, or until the women is established labor (whichever sooner)~* Penicillin may be used in patients who can't tolerate erythromycin~* In cases of penicillin allergy: Cefazolin 1 g intravenously every 8 hours for 48 hours, followed by cephalexin 500 mg orally four times daily for five days. These drugs provide coverage for both GBS and Escherichia coli, the two major causes of neonatal infection.
Study NCT05664360 — intervention group
Intervention type: OTHER
Intervention: Age (young versus older)
Description: Age
Study NCT03811691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI exam
Description: Pacing system safety and stability under MRI scan environment
Study NCT03054233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crossed leg sitting position
Description: Spinal anesthesia done in crossed leg sitting position
Study NCT02107131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal ranibizumab 0.3mg
Study NCT02757144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Nexium®
Study NCT01559675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone High Dose
Description: Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
Study NCT01559675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Low Dose
Description: 1/3 IV equivalent dose (IVED) (hydrocortisone equivalent of the patient's preoperative steroid dose) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD 1), followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
Study NCT03953469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Passiflora incarnata
Description: One-time administration of 1/8 tsp solid extract Passiflora incarnata providing 900mg of Passiflora incarnata
Study NCT01751100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Test Offer
Description: HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test
Study NCT01751100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Health Screen Offer
Description: A Research Assistant (RA) will provide health education on diabetes, hypertension, and HIV. The RA will then offer free blood pressure check, blood glucose measuring, rapid Hepatitis C (HCV) test, and a free, rapid oral HIV test.
Study NCT03285269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Protocol
Description: Ultrasound of the inferior vena cava, heart and lungs.
Study NCT03285269 — intervention group
Intervention type: DEVICE
Intervention: Bioreactance
Description: Bioreactance assessment using Cheetah Bioreactance Device (FDA Approved). Bioreactance is a non-invasive measure of cardiac output.
Study NCT03285269 — intervention group
Intervention type: PROCEDURE
Intervention: Passive Leg Raise
Description: A passive leg raise involves placing the patient supine and raising the legs to simulate an intravenous fluid bolus.
Study NCT04095182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zebinix 400mg
Description: Zebinix 400mg group is administered with two Zebinix 200mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\~11)
Study NCT04095182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Zebinix 400mg
Description: Placebo for Zebinix 400mg group is administered with two placebo for Zebinix 200mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)
Study NCT04095182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zebinix 800mg
Description: Zebinix 800mg group is administered with a Zebinix 800mg tablet per day. (Single dose: Day 1, Multiple dose: Day5\~11)
Study NCT04095182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Zebinix 800mg
Description: Placebo for Zebinix 800mg group is administered with a placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)
Study NCT04095182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zebinix 1600mg
Description: Zebinix 1600mg group is administered with two Zebinix 800mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\~11)
Study NCT04095182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Zebinix 1600mg
Description: Placebo for Zebinix 1600mg group is administered with two placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)
Study NCT02155777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OrthoNovum 1/35
Study NCT04093713 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: A novel technique to block the inferior alveolar nerve block using Mepivecaine with Levonordefrin
Description: blocking the inferior alveolar nerve using extroral landmarks
Study NCT05140460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cultural Pride Reinforcement for Early School Readiness (CPR4ESR)
Description: The intervention entails distribution of a children's book with a cultural pride theme and the cultural pride parent book-sharing guide. Intervention participants select and receive a developmentally appropriate (baby, toddler, or preschool) book that features African American, Latino, Asian or diverse cultural pride perspectives.
Study NCT05140460 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reach Out and Read (ROR)
Description: The control condition involves distribution of a standard ROR book and book-sharing advice. Distributed books are developmentally appropriate (baby, toddler, or preschool).
Study NCT04977713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: A researcher sat behind the women to comfortably access the sacral area and be in the appropriate position. The researcher then applied deep rotational pressure on the BL32 points until her nail bed colour changed to prevent any discomfort in the participants
Study NCT04977713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shower
Description: During uterine contractions, these participants took a shower while standing, with a researcher on hand to assist her (average time: 20 minutes). The water's temperature was between 22°C and 26°C.
Study NCT04198480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT103
Description: 2 mg/kg subcutaneously (SC) every 4 weeks with a loading dose of 2 mg/kg SC on study days 8 and 15.
Study NCT01591941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core-PAC
Description: Core position and control movement strategy (Core-PAC):~Do warm-up prior to 6 weeks of regular soccer training for peak flexion angles and peak abduction moments at the knee during a side-cut (SC) and an unanticipated side-cut (USC) prior to kicking a soccer ball and a side-hop (SH) task.
Study NCT05335824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The platelet-rich plasma (PRP)
Description: Twenty ml of venous blood was drawn from each patient with the use of PRP tubes that contain anticoagulant citrate dextrose. The double-spin technique was used to prepare the PRP. The injection areas were anesthetized with lidocaine 2% with epinephrine 1/80000 and left for 10 minutes. 15 units (0. 15 mL) of PRP were injected interaligamentlly in the middle, distobuccal, and distopalatal areas of the distal surface of the upper canines (5 units in each area) together with submucosal injections buccally and palatally (100 units and 50 units~, respectively).
Study NCT05335824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The injectable platelet-rich fibrin (I-PRF) group
Description: Twenty ml of venous blood was drawn from each patient in this experimental group.~I-PRF was prepared with the use of 20 ml of blood drawn from the patient in dry sterile tubes without anticoagulant (quickly before coagulation starts) by following the centrifugation protocol requires one cycle only (700 RPM for 3 minutes) Injection procedures, sites, and time were similar to the PRP group.
Study NCT05335824 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The control group
Description: NiTi closed-coil springs (American Orthodontics, Sheboygan, WI) were used to impose 150 g force from the first molar band hook to the bracket of canine on each side on 0.019\*0.025-in SS archwire Patients' follow-up appointments were two weeks intervals; at each visit, the force produced by the coil was checked and readjusted when needed in order to keep it at 150-g level and the appliances were examined for any deformation or change in the position because of chewing. Canine retraction continued until achieving Class I canine relationship.
Study NCT03348540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Training
Description: Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
Study NCT03348540 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparison Task
Description: Neutral- neutral stimuli prior to response task
Study NCT03757819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Brain Stimulation
Study NCT02652975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEXA scan
Description: Measurements of body composition: Total body fat and fat free mass is measured by Dual Energy X-ray Absorptiometry (DEXA).
Study NCT02652975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Laboratory blood samples
Description: Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).~Further more urine samples to determine possible systemic impact of cardiovascular disease.~We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.~Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen.
Study NCT03757819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM
Description: Placebo device
Study NCT03720717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 10mg
Description: Baclofen administration pre-operatively
Study NCT03720717 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration
Study NCT00666952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet Decision Aid
Description: General educational booklet on gastrointestinal surgery developed by the NIH titled, 'Gastrointestinal Surgery for Severe Obesity'.
Study NCT02255045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: 1 Meloxicam Vaginal Ring (MVR) for 4-6 days
Study NCT01591941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core-PAC
Description: Core position and control movement strategy (Core-PAC):~Do warm-up prior to 6 weeks of regular soccer training for peak flexion angles and peak abduction moments at the knee during a side-cut (SC) and an unanticipated side-cut (USC) prior to kicking a soccer ball and a side-hop (SH) task.
Study NCT03359850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
Study NCT03998267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Droobi
Description: A new mobile application, specifically built for the diabetes patients in Qatar with the help of local expertise.
Study NCT03998267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care including physicians, dietetics and diabetes educators support
Study NCT03998267 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care including physicians, dietetics and diabetes educators support
Study NCT01075789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine
Description: Lignocaine 10% solution administered intra nasally plus lignocaine 2% solution administered orally.
Study NCT01075789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Viscous, coloured, sucrose flavoured gel solution to match xylocaine viscous in appearance, normal saline administered intranasally to the nasal turbinates and nasopharynx.
Study NCT02124213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg PF-06412562
Description: Subject will receive a single dose of 30 mg PF-06412562
Study NCT02124213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562
Description: The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
Study NCT02124213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562
Description: The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.~This Cohort is optional.
Study NCT03895333 — intervention group
Intervention type: OTHER
Intervention: Audiological profiling and bone mineral densitometry measurement
Description: bone mineral densitometry measurements and hearing test patients, osteoporosis according to whether the hearing test will be analyzed.
Study NCT00950846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Day -9, -8, -7 and -6~Patients less than or equal to 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients >12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses.
Study NCT03010228 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA15 with Alum
Description: I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
Study NCT03010228 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA15 without Alum
Description: I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
Study NCT00950846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: (50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours (can be given over 1 to 4 hours as determined by the treating physician). The total dose to be given over 4 days is 200 mg/kg.
Study NCT00950846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2/day IV over 1 hour for patients greater than 10 kg, or 1.3 mg/kg/day for patients less than or equal to 10 kg.
Study NCT00950846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Blood Stem Cell Infusion
Description: The cord blood stem cells will be infused on Day 0.
Study NCT00165178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Induction Phase: Given orally or intravenously Days 0-28 Intensification Phase: Given orally Days 1-5 of each cycle Continuation Phase: Given orally Days 1-5 of each cycle
Study NCT02255045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Potassium
Description: 1 tablet 50 mg diclofenac every 12 hours for 4-6 days
Study NCT02255045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral
Description: 1 placebo tablet every 12 hours for 4-6 days
Study NCT02255045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral
Description: 1 placebo tablet every 12 hours for 4-6 days
Study NCT02255045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Vaginal
Description: 1 placebo vaginal ring for 4-6 days
Study NCT02255045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal
Description: 1 placebo vaginal ring for 4-6 days
Study NCT03673124 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribociclib
Description: 600 mg by mouth daily for 21 days followed by 7 days off treatment
Study NCT03673124 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: 2.5 mg by mouth daily
Study NCT03762642 — intervention group
Intervention type: PROCEDURE
Intervention: Mastectomy
Description: Removal of the whole breast
Study NCT03762642 — intervention group
Intervention type: PROCEDURE
Intervention: Breast-Conserving Surgery
Description: Removal of the cancerous tissue only
Study NCT00165178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Intensification Phase: Given orally days 1-5 of each cycle Continuation Phase: Given orally days 1-5 pf each cycle
Study NCT00165178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Induction Phase: Intravenously on Days 0,1 Intensification Phase: Intravenously on Day 1 of each cycle
Study NCT00165178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: Induction Phase: Intravenously on Days 0,1 Intensification Phase: Intravenously on Day 1 of each cycle
Study NCT00165178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E. coli asparaginase
Description: Intensification Phase: In the muscle weekly. Dose will vary
Study NCT00165178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E. coli asparaginase
Description: Intensification Phase: In the muscle weekly. Dose will vary
Study NCT00165178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Induction: Intravenously on days 0, 7, 14, 21 MLL Intensification Phase: Intravenously on Days 1, 8, 15, 22 CNS Therapy: Intravenously on Day 1 Intensification Phase: Intravenously on day 1 of each cycle Continuation Phase: Intravenously on Day 1 of each cycle
Study NCT00165178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: Induction: Intravenously on days 0, 7, 14, 21 MLL Intensification Phase: Intravenously on Days 1, 8, 15, 22 CNS Therapy: Intravenously on Day 1 Intensification Phase: Intravenously on day 1 of each cycle Continuation Phase: Intravenously on Day 1 of each cycle
Study NCT01003470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Xing Nao Kai Qiao Acupuncture
Study NCT01003470 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: Kinesitherapy
Study NCT01003470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture and rehabilitation
Description: Xing Nao Kai Qiao Acupuncture plus Kinesitherapy
Study NCT01283009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Substance
Description: Inactive Substance will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
Study NCT01283009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
Study NCT04025866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: 1h/day for 5 days/week of conventional rehabilitation for femur fracture
Study NCT04025866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: 30 min/day of aerobic exercise with arm cycle ergometer added to 1h/day for 5 days/week of conventional rehabilitation for femur fracture
Study NCT00909857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)
Description: Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
Study NCT00909857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl estradiol, Levonorgestrel (Miranova)
Description: Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
Study NCT00909857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Match to SH T00658ID
Description: Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
Study NCT00909857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Match to SH D593B
Description: Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.